drugset / Trial / NCT06331286

The Effect of Dulaglutide as an Adjuvant Therapy on Cognitive Function in Bipolar Disorder Patients With Obesity

NCT06331286

RandomizedParallel-groupOpen-labelTreatment

Summary

The primary objective of this study is to investigate the effect of dulaglutide adjuvant treatment in patients with bipolar disorder with obesity, in addition to exploring the effect of GLP-1RA on cognition of bipolar disorder.

Timeline

Start
2023-09-01
Primary completion
2024-12-31
Completion
2024-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Dulaglutide Peptide 0.75 mg Subcutaneous